Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ArriVent BioPharma, Inc. filings document a Nasdaq-listed clinical-stage oncology company with common stock registered under the Exchange Act. Its Form 8-K reports cover financial results, Regulation FD disclosures, clinical and preclinical program announcements, conference presentations, IND-related updates, material-event disclosures, and exhibits tied to press releases.
Proxy materials describe stockholder voting matters, board elections, auditor ratification, annual meeting procedures, and governance information. The filing record also reflects capital-structure disclosures, emerging growth company status, material agreements, and risk-oriented disclosures associated with ArriVent's firmonertinib program and antibody-drug conjugate pipeline.
ArriVent BioPharma’s Chief Financial Officer Winston Kung received a stock option grant reported on this Form 4. On February 2, 2026, he was awarded an option to purchase 140,000 shares of common stock at an exercise price of $22.67 per share.
The option vests over time, with 25% of the underlying shares vesting on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on his continued service with the company through each vesting date. The option expires on February 2, 2036.
ArriVent BioPharma’s President and CEO, Zhengbin Yao, reported a new stock option grant. On February 2, 2026, he received an option to purchase 550,000 shares of common stock at an exercise price of $22.67 per share.
According to the filing, 25% of the option vests on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, he beneficially owns 550,000 derivative securities directly.
ArriVent BioPharma’s General Counsel, James Paul Kastenmayer, received a stock option grant reported on a Form 4. He was awarded options covering 130,000 shares of common stock at an exercise price of $22.67 per share.
The option was granted on February 2, 2026. The underlying shares vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on his continued service. Following this grant, he beneficially owns 130,000 stock options directly.
Hillhouse-affiliated investment entities reduced their stake in ArriVent BioPharma, Inc. A group of vehicles managed by Hillhouse Investment Management and HHLR Advisors reported selling 555,555 shares of ArriVent common stock on December 10, 2025 at $23.37 per share.
After this sale, the reporting group indirectly held 3,929,117 ArriVent shares through entities including HACF, L.P., VSUM VI Holdings Limited, VSUM VIII Holdings Limited and ARVT Holdings Limited. Hillhouse Investment Management, Ltd. and HHLR Advisors, Ltd. filed jointly as 10% owners and expressly disclaim beneficial ownership beyond their pecuniary interests.
The Vanguard Group reported beneficial ownership of 1,869,266 shares of ArriVent Biopharma Inc. common stock, representing 4.52% of the class as of 12/31/2025. Vanguard has no sole voting or dispositive power, with shared voting power over 242,661 shares and shared dispositive power over 1,869,266 shares.
Vanguard states that these securities are held in the ordinary course of business and not to change or influence control of ArriVent. Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, with no single client holding more than 5%. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Arrivent Biopharma Inc. common stock. BlackRock reports beneficial ownership of 2,319,341 shares, representing 5.6% of Arrivent’s outstanding common shares as of the event date.
The filing states that BlackRock has sole power to vote 2,279,791 shares and sole power to dispose of all 2,319,341 shares, with no shared voting or dispositive power. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arrivent Biopharma.
ArriVent BioPharma (AVBP) filed its Q3 2025 10-Q, reporting a net loss of $34,978 thousand for the quarter and $130,764 thousand year-to-date as it advances oncology programs led by firmonertinib. Operating expenses rose with research and development at $32,167 thousand in Q3 (driven by Phase 3 FURVENT and early-stage programs) and general and administrative at $6,149 thousand. Interest and investment income was $3,338 thousand.
Liquidity strengthened: cash and cash equivalents were $112,672 thousand and short-term investments were $187,594 thousand at September 30, 2025. The company states aggregate cash, cash equivalents and marketable securities of $305.4 million as of September 30, 2025 are sufficient to sustain planned operations through at least twelve months from the issuance date. Capital actions included $87.3 million net through an at-the-market program and $80.6 million net from a July underwritten offering. A $75.0 million term loan facility remains undrawn. Clinical updates highlight firmonertinib across multiple EGFR-mutant NSCLC settings, including a pivotal Phase 3 and a planned randomized Phase 3 study. Shares outstanding were 41,281,361 as of November 7, 2025.
ArriVent BioPharma, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. On November 10, 2025, the company issued a press release with these quarterly results, which is attached as Exhibit 99.1.
The company specifies that the press release and the related disclosure are being furnished rather than filed under U.S. securities laws, meaning they are not subject to certain liability provisions and are not automatically incorporated into other SEC filings.
ArriVent BioPharma, Inc. filed a report describing a new corporate update related to its lung cancer drug development work. The company issued a press release announcing that it presented the final analysis of firmonertinib monotherapy data from its global phase 1b study in EGFR PACC mutant non-small cell lung cancer at the 2025 World Conference on Lung Cancer.
The press release is included as Exhibit 99.1 and most of its contents are incorporated by reference into this report, while being furnished rather than filed for securities law purposes.
Novo Holdings A/S reports beneficial ownership of 1,872,142 shares of ArriVent BioPharma, representing 4.99% of the company's common stock. The filing states Novo Holdings has sole voting and sole dispositive power over these shares and does not share voting or dispositive power with any other party.
The filer is a Denmark-based investment holding company that manages assets for the Novo Nordisk Foundation and clarifies the Foundation is not deemed to beneficially own the shares held by Novo Holdings. The filing indicates the position is held without intent to change or influence control of ArriVent.